Cargando…
Critical appraisal of ranibizumab in the treatment of diabetic macular edema
Diabetic retinopathy is the leading cause of blindness among individuals of working age in industrialized nations, with most of the vision loss resulting from diabetic macular edema (DME). The formation of DME depends on the action of several growth factors and inflammatory mediators, but vascular e...
Autor principal: | Stewart, Michael W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699322/ https://www.ncbi.nlm.nih.gov/pubmed/23836955 http://dx.doi.org/10.2147/OPTH.S36443 |
Ejemplares similares
-
Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema
por: Bandello, Francesco, et al.
Publicado: (2011) -
Renal Biomarkers for Treatment Effect of Ranibizumab for Diabetic Macular Edema
por: Lai, Ivan Pochou, et al.
Publicado: (2020) -
Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab
por: Keane, Pearse A, et al.
Publicado: (2011) -
Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
por: Fong, Angie HC, et al.
Publicado: (2013) -
Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema
por: Demircan, Ali, et al.
Publicado: (2018)